Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Linagliptin and metformin hydrochloride (Jentadueto) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• The information comes from a single study, a randomized controlled trial.
• In the study, Jentadueto was compared with metformin alone. Both were combined with lifestyle changes in patients who have impaired glucose tolerance plus two risk factors for type 2 diabetes.
• Compared to using only metformin, the combination of linagliptin and metformin showed superior effectiveness in enhancing glucose metabolism, improving pancreatic β-cell function, reducing progression from prediabetes to type 2 diabetes, and increasing chances of achieving normoglycemia.
• No major side effects were observed during the study for either group, indicating that both treatment regimens are well tolerated by this specific population subgroup.
• This suggests that Jentadueto might be particularly beneficial for preventing progression to type 2 diabetes among individuals characterized by impaired glucose tolerance along with at least two other risk factors when used alongside lifestyle modifications.